This study was designed to determine the safety, tolerance, and pharmacokinetics of BMS 180194 when given orally to HIV- and CMV- seropositive subjects twice daily for 28 days. During the course of the period covered by this report, we completed the clinical portion of the study.
Showing the most recent 10 out of 1014 publications